Search for a trial

Non-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated With Unrestricted Use of the Healing-Targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy After 1-month of Dual-antiplatelet Therapy: The PIONEER IV trial

This PIONEER IV trial aims to demonstrate a non-inferiority of QFR-guidance PCI to usual care PCIwith respect to Patient oriented Composite Endpoint (PoCE) at 1 year with the unrestricted use ofHT Supreme-SES in an all-comers…